Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CITIZENS FINANCIAL GROUP INC/RICFG · Entity 1913 | Director | February 14, 2019 | February 15, 2019 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | July 02, 2026 | July 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CITIZENS FINANCIAL GROUP INC/RI
Report date February 14, 2019 · Filed February 15, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,993.604 |
Reported balance
After 2019-02-14 transaction · row 1
1 source rowRow 1 · 2019-02-14 · Grant · Acquired 30.91 · Balance 60,993.604 F1: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan.
REGENERON PHARMACEUTICALS, INC.
Report date July 02, 2026 · Filed July 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,303 |
Reported balance
After 2026-07-02 transaction · row 1
1 source rowRow 1 · 2026-07-02 · Sale · Disposed 200 · Balance 17,303 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F2: Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025.
F2: Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2020 Filed May 4, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $522.61 | $3,658.27 |
DisclosureSEC source: 0001708138-20-000046 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,852 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on May 1, 2020 at prices ranging from $522.40 to $522.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2020 at each separate price. Read SEC document |
| May 01, 2020 Filed May 4, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 17 | $521.36 | $8,863.12 |
DisclosureSEC source: 0001708138-20-000046 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,859 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 17 shares of Company stock on May 1, 2020 at prices ranging from $521.13 to $521.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2020 at each separate price. Read SEC document |
| May 01, 2020 Filed May 4, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 22 | $520.46 | $11,450.12 |
DisclosureSEC source: 0001708138-20-000046 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,876 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 22 shares of Company stock on May 1, 2020 at prices ranging from $520.01 to $520.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2020 at each separate price. Read SEC document |
| May 01, 2020 Filed May 4, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 18 | $519.54 | $9,351.72 |
DisclosureSEC source: 0001708138-20-000046 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,898 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 18 shares of Company stock on May 1, 2020 at prices ranging from $519.01 to $519.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2020 at each separate price. Read SEC document |
| May 01, 2020 Filed May 4, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 15 | $518.57 | $7,778.55 |
DisclosureSEC source: 0001708138-20-000046 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,916 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 15 shares of Company stock on May 1, 2020 at prices ranging from $518.10 to $518.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2020 at each separate price. Read SEC document |
| May 01, 2020 Filed May 4, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 12 | $517.41 | $6,208.92 |
DisclosureSEC source: 0001708138-20-000046 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,931 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 12 shares of Company stock on May 1, 2020 at prices ranging from $517.00 to $517.55. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2020 at each separate price. Read SEC document |
| April 01, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $495.66 | $495.66 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 26 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,943 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $493.35 | $493.35 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 25 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,944 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $492.71 | $1,478.13 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 24 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,945 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F22 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on April 1, 2020 at prices ranging from $492.41 to $492.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. Read SEC document |
| April 01, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $491.13 | $982.26 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 23 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,948 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F21 · price: Represents volume-weighted average price of sales of 2 shares of Company stock on April 1, 2020 at prices ranging from $491.11 to $491.14. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. Read SEC document |
| April 01, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $490.35 | $490.35 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 22 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,950 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $489.56 | $2,447.80 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 21 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,951 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F20 · price: Represents volume-weighted average price of sales of 5 shares of Company stock on April 1, 2020 at prices ranging from $489.29 to $489.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. Read SEC document |
| April 01, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10 | $488.62 | $4,886.20 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 20 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,956 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F19 · price: Represents volume-weighted average price of sales of 10 shares of Company stock on April 1, 2020 at prices ranging from $488.06 to $488.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. Read SEC document |
| April 01, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $487.54 | $487.54 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 19 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,966 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $486.53 | $1,946.12 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 18 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,967 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F18 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on April 1, 2020 at prices ranging from $486.27 to $486.71. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. Read SEC document |
| April 01, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $485.65 | $1,456.95 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 17 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,971 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F17 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on April 1, 2020 at prices ranging from $485.60 to $485.70. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. Read SEC document |
| April 01, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8 | $484.54 | $3,876.32 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 16 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,974 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F16 · price: Represents volume-weighted average price of sales of 8 shares of Company stock on April 1, 2020 at prices ranging from $484.14 to $484.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. Read SEC document |
| April 01, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 11 | $483.49 | $5,318.39 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 15 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,982 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F15 · price: Represents volume-weighted average price of sales of 11 shares of Company stock on April 1, 2020 at prices ranging from $483.13 to $483.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. Read SEC document |
| April 01, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 14 | $482.43 | $6,754.02 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 14 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,993 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F14 · price: Represents volume-weighted average price of sales of 14 shares of Company stock on April 1, 2020 at prices ranging from $482.01 to $482.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. Read SEC document |
| April 01, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $481.34 | $1,925.36 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 13 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,007 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on April 1, 2020 at prices ranging from $481.04 to $481.69. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. Read SEC document |
| April 01, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8 | $480.55 | $3,844.40 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 12 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,011 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 8 shares of Company stock on April 1, 2020 at prices ranging from $480.16 to $480.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. Read SEC document |
| April 01, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 18 | $479.60 | $8,632.80 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 11 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,019 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 18 shares of Company stock on April 1, 2020 at prices ranging from $479.23 to $479.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. Read SEC document |
| April 01, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $478.45 | $1,913.80 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,037 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on April 1, 2020 at prices ranging from $478.12 to $478.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. Read SEC document |
| April 01, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $477.58 | $955.16 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,041 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 2 shares of Company stock on April 1, 2020 at prices ranging from $477.55 to $477.60. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $469.49 | $1,877.96 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,043 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 24 | $468.14 | $11,235.36 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,047 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 24 shares of Company stock on March 30, 2020 at prices ranging from $468.00 to $468.56. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 30, 2020 at each separate price. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 19 | $467.51 | $8,882.69 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,071 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 19 shares of Company stock on March 30, 2020 at prices ranging from $467.00 to $467.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 30, 2020 at each separate price. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 23 | $466.60 | $10,731.80 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,090 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 23 shares of Company stock on March 30, 2020 at prices ranging from $466.05 to $466.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 30, 2020 at each separate price. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 16 | $465.35 | $7,445.60 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,113 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 16 shares of Company stock on March 30, 2020 at prices ranging from $465.00 to $465.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 30, 2020 at each separate price. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 9 | $464.49 | $4,180.41 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,129 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 9 shares of Company stock on March 30, 2020 at prices ranging from $464.14 to $464.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 30, 2020 at each separate price. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $463.16 | $1,389.48 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,138 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on March 30, 2020 at prices ranging from $463.09 to $463.30. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 30, 2020 at each separate price. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 22:49 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $462.80 | $925.60 |
DisclosureSEC source: 0001708138-20-000024 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,141 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 2 shares of Company stock on March 30, 2020 at prices ranging from $462.71 to $462.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 30, 2020 at each separate price. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,361 | $0.00 Strike: $374.12 | $0.00 |
DisclosureSEC source: 0001237899-20-000002 · edgardoc.xml · derivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,361 Underlying: Common Stock · 4,361 shares Expires 2030-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 320 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-20-000002 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,143 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 26, 2019 Filed Nov 3, 2020 22:22 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-20-000046 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,323 Read SEC document |
| November 22, 2019 Filed Nov 3, 2020 22:22 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-20-000046 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,323 Read SEC document |
| February 14, 2019 Filed Feb 15, 2019 19:56 UTC | CITIZENS FINANCIAL GROUP INC/RI CFG · Entity 1913 | GrantCommon Stock | 30.91 | $0.00 | $0.00 |
DisclosureSEC source: 0000759944-19-000015 · wf-form4_155026057632195.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,993.604 F1 · shares: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,784 | $0.00 Strike: $371.40 | $0.00 |
DisclosureSEC source: 0001237899-19-000001 · edgardoc.xml · derivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,784 Underlying: Common Stock · 3,784 shares Expires 2029-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 323 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000001 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,823 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 21:38 UTC | CITIZENS FINANCIAL GROUP INC/RI CFG · Entity 1913 | GrantCommon Stock | 25.665 | $0.00 | $0.00 |
DisclosureSEC source: 0000759944-18-000096 · wf-form4_154240428628193.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,962.694 F1 · shares: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan. Read SEC document |
| August 21, 2018 Filed Jan 4, 2019 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000001 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,500 Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 20:22 UTC | CITIZENS FINANCIAL GROUP INC/RI CFG · Entity 1913 | GrantCommon Stock | 23.222 | $0.00 | $0.00 |
DisclosureSEC source: 0000759944-18-000069 · wf-form4_153445093543405.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,937.029 F1 · shares: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan. Read SEC document |
| May 16, 2018 Filed May 17, 2018 20:59 UTC | CITIZENS FINANCIAL GROUP INC/RI CFG · Entity 1913 | GrantCommon Stock | 17.59 | $0.00 | $0.00 |
DisclosureSEC source: 0000759944-18-000054 · wf-form4_152659068706235.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,913.807 F1 · shares: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan. Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 20:42 UTC | CITIZENS FINANCIAL GROUP INC/RI CFG · Entity 1913 | GrantCommon Stock | 2,977 | $0.00 | $0.00 |
DisclosureSEC source: 0000759944-18-000043 · wf-form4_152486172067085.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,896.217 F1 · shares: Reflects a restricted stock unit award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 20:57 UTC | CITIZENS FINANCIAL GROUP INC/RI CFG · Entity 1913 | GrantCommon Stock | 2.018 | $0.00 | $0.00 |
DisclosureSEC source: 0000759944-18-000007 · wf-form4_151881460802794.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,919.217 F1 · shares: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan. Read SEC document |
| February 14, 2018 Filed Jan 4, 2019 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000001 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,439 | $0.00 Strike: $380.95 | $0.00 |
DisclosureSEC source: 0001708138-18-000001 · edgardoc.xml · derivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,439 Underlying: Common Stock · 7,439 shares Expires 2028-01-02 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 15, 2017 Filed Nov 16, 2017 21:46 UTC | CITIZENS FINANCIAL GROUP INC/RI CFG · Entity 1913 | GrantCommon Stock | 1.983 | $0.00 | $0.00 |
DisclosureSEC source: 0000759944-17-000079 · wf-form4_151086876824846.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,917.199 F1 · shares: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 20:46 UTC | CITIZENS FINANCIAL GROUP INC/RI CFG · Entity 1913 | GrantCommon Stock | 2.216 | $0.00 | $0.00 |
DisclosureSEC source: 0000759944-17-000069 · wf-form4_150308916382480.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,915.216 F1 · shares: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer under the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 20:57 UTC | CITIZENS FINANCIAL GROUP INC/RI CFG · Entity 1913 | GrantCommon Stock | 418 | $0.00 | $0.00 |
DisclosureSEC source: 0000759944-17-000056 · wf-form4_150179383740520.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,913 F1 · shares: Reflects a restricted stock unit award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.